JP2003530872A5 - - Google Patents

Download PDF

Info

Publication number
JP2003530872A5
JP2003530872A5 JP2001578467A JP2001578467A JP2003530872A5 JP 2003530872 A5 JP2003530872 A5 JP 2003530872A5 JP 2001578467 A JP2001578467 A JP 2001578467A JP 2001578467 A JP2001578467 A JP 2001578467A JP 2003530872 A5 JP2003530872 A5 JP 2003530872A5
Authority
JP
Japan
Prior art keywords
polypeptide
polynucleotide
symbol
seq
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001578467A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003530872A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/013828 external-priority patent/WO2001081380A2/en
Publication of JP2003530872A publication Critical patent/JP2003530872A/ja
Publication of JP2003530872A5 publication Critical patent/JP2003530872A5/ja
Pending legal-status Critical Current

Links

JP2001578467A 2000-04-27 2001-04-27 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物 Pending JP2003530872A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20007400P 2000-04-27 2000-04-27
US60/200,074 2000-04-27
PCT/US2001/013828 WO2001081380A2 (en) 2000-04-27 2001-04-27 Immunogenic pneumococcal protein and vaccine compositions thereof

Publications (2)

Publication Number Publication Date
JP2003530872A JP2003530872A (ja) 2003-10-21
JP2003530872A5 true JP2003530872A5 (https=) 2008-07-03

Family

ID=22740214

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001578467A Pending JP2003530872A (ja) 2000-04-27 2001-04-27 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物

Country Status (6)

Country Link
US (1) US6689369B2 (https=)
EP (1) EP1278856A2 (https=)
JP (1) JP2003530872A (https=)
AU (2) AU2001255772B2 (https=)
CA (1) CA2407455A1 (https=)
WO (1) WO2001081380A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US6858706B2 (en) * 1998-04-07 2005-02-22 St. Jude Children's Research Hospital Polypeptide comprising the amino acid of an N-terminal choline binding protein a truncate, vaccine derived therefrom and uses thereof
DE69942176D1 (de) * 1998-04-07 2010-05-06 Medimmune Llc Choline-bindende proteine derivate aus pneumokoken als impfstoff
EP2277897A1 (en) 2001-04-16 2011-01-26 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
JP5867952B2 (ja) 2009-06-10 2016-02-24 ノバルティス アーゲー ベンゾナフチリジン含有ワクチン
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt) 2009-12-15 2017-12-26 Novartis Ag suspensão homogênea de compostos de imunopotenciação e usos dos destes
EA031379B1 (ru) 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Streptococcuspneumoniae抗原の増強された製剤
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
JP7362667B2 (ja) 2018-02-12 2023-10-17 イニミューン・コーポレーション Toll様受容体リガンド
JP2023547677A (ja) 2020-11-04 2023-11-13 エリゴ・バイオサイエンス キューティバクテリウム・アクネス組換えファージ、その産生方法及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006734A1 (en) * 1996-08-16 1998-02-19 Smithkline Beecham Corporation Novel prokaryotic polynucleotides, polypeptides and their uses
JP4469026B2 (ja) 1996-10-31 2010-05-26 ヒューマン ジノーム サイエンシーズ,インコーポレイテッド Streptococcus pneumoniaeの抗原およびワクチン

Similar Documents

Publication Publication Date Title
JP2003530872A5 (https=)
JP7641512B2 (ja) Tlr7アゴニストにカップリングする新規コロナウイルスポリペプチドワクチンおよびその適用
AU2007271350B2 (en) Small Streptococcus pyogenes antigens and their use
JP2002542827A5 (https=)
CA2371714A1 (en) Streptococcus pneumoniae proteins and vaccines
RU2757426C2 (ru) Иммунногенный слитый белок
JP2008529558A5 (https=)
JP2002507396A5 (https=)
RU2008150400A (ru) Новая детерминанта вирулентности в пределах структурного гликопротеина е2 вируса классической лихорадки свиней
WO2001045639A3 (en) Methods for protecting against lethal infection with bacillus anthracis
CN103068838A (zh) 基于重组蛋白的抗链球菌感染疫苗
JP5437813B2 (ja) S.アガラクティエの防御タンパク質、その組み合わせ、およびそれを使用する方法
JP2002512800A5 (https=)
KR102675880B1 (ko) SARS-CoV-2 스파이크 단백질 및 면역글로불린의 Fc 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
CN118873646A (zh) 一种抑制a组链球菌感染的重组蛋白疫苗及其应用
KR102675879B1 (ko) SARS-CoV-2 스파이크 단백질 S1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
KR102675881B1 (ko) Pedv 스파이크 단백질 s1 유래 단백질 및 페리틴 유래 단백질을 포함하는 재조합 단백질 및 이의 용도
Stanley Progress towards an amebiasis vaccine
JP2024512722A (ja) 免疫原性融合タンパク質
CN107974458A (zh) 表达猪丹毒杆菌重组蛋白GAPDH的基因gapdh及其重组大肠杆菌与应用
CN114437235A (zh) 马链球菌马亚种8种蛋白的重组融合蛋白及其制备方法和应用
US7041295B2 (en) Compounds for treatment of infectious and immune system disorders and methods for their use
JP2004502782A5 (https=)
WO2023044327A1 (en) Recombinant vaccine compositions
Yu et al. A DNA vaccine encoding the FMDV capsid precursor polypeptide P1 and the enhancing effect of bovine herpesvirus 1 VP22 protein as molecular adjuvant.